What are the major cortical networks we are trying to change with TMS? Where will TMS fit into psychiatry in the next decade? These questions and more are addressed in this podcast.
Transcranial Magnetic Stimulation
An expert Q&A about the experience of TMS treatment and the future of neuromodulation as it transitions from research to practice.
It’s an FDA approved technology, but what exactly is TMS and why should you be aware of it?
This slideshow provides a snapshot of innovative alternatives to traditional treatments for psychiatric disorders.
This article describes challenges for psychiatrists striving to ensure informed consent for, and for patients who may lack full appreciation of the risks and benefits of, neurostimulation.
Among patients with treatment-resistant MDD, transcranial magnetic stimulation wins the popular vote.
Researchers looked into the efficacy and value of TMS for treatment-resistant depression.
The potential of TMS as a treatment for cognitive disorders, fatigue, pain, and other manifestations of brain disease is discussed, as is the encouraging prospect for neuropsychiatric management of many patients.
Available data suggest that transcranial magnetic stimulation holds promise as a treatment for GAD. Here: a look at what we know.
We have medications that can affect serotonin, norepinephrine, and—to a lesser extent—dopamine. Many other neurotransmitters are involved with mood disorders, but we have no medications yet to target them. Neurostimulation offers a non-systemic somatic approach to depression, often with an improved side effect profile. More in this Q&A.